3-[(4R)-4-aminocyclopent-2-en-1-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaene-12,14-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-[(4R)-4-aminocyclopent-2-en-1-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaene-12,14-dione
• 化学式: C₂₅H₁₈N₄O₂
• 分子量: 406.4
• InChiKey: RESWEKNZHHULKI-UEWDXFNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  1
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  92.9
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• US7262215B2
  申请人：——

  公开号：US7262215B2

  公开（公告）日：2007-08-28
• [EN] N-CARBACYCLE MONOSUBSTITUTED INDOLOCARBAZOLES AS PROTEIN KINASE INHIBITORS<br/>[FR] INDOLOCARBAZOLES MONOSUBSTITUES A N-CARBACYCLES UTILISES COMME INHIBITEURS DE PROTEINE-KINASE
  申请人：NAD AG

  公开号：WO2003051887A1

  公开（公告）日：2003-06-26

  This invention relates to N-carbacycle monosubstituted indolocarbazole compounds. Furthermore, this invention relates to medicaments comprising N-carbacycle monosubstituted indolocarbazoles compounds and the use of such compounds for treating non-insulin dependent diabetes mellitus, acute stroke and other neurotraumatic injuries, for treating diabetes mellitus, as a chemotherapeutic for the treatment of various malignant diseases, for treating diseases caused by malfunctioning of specific signaling pathways, and for treating neurodegenerative diseases such as for example Alzheimer's disease.